Canaccord Genuity analyst Matt Bottomley maintained a Sell rating on Cronos Group (NASDAQ:CRON) on Monday, setting a price target of C$7.5, which is approximately 30.36% below the present share price of $8.87.
Bottomley expects Cronos Group to post earnings per share (EPS) of -$0.44 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Hold rating of shares in Cronos Group, with an average price target of $8.39.
The analysts price targets range from a high of $11 to a low of $6.18.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $12.61 million and a net profit of -$43.46 million. The company's market cap is $3.3 billion.
According to TipRanks.com, Canaccord Genuity analyst Matt Bottomley is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 29.0% and a 54.30% success rate.
Cronos Group, Inc. engages in the production and sale of cannabis in federally legal jurisdictions, including Canada and Germany. Its portfolio includes Peace Naturals, Original BC (OGBC) and Whistler Medical Marijuana Company (WMMC). The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.